Angiogenin (ANG) has been extensively reported across a variety of malignant diseases, including gestational trophoblast neoplasia (5, 6), prostate cancer (7, 8), bladder cancer (9–13), nasopharyngeal carcinoma (14, 15), colorectal cancer (16, 17), hepatocellular carcinoma (18), pancreatic cancer (19), renal cell carcinoma (20), gastric and colon cancer (21), lung cancer (22, 23), breast cancer (24, 25), multiple myeloma (26), lymphoma (27, 28), oral cancer (29), neuroblastoma (30), melanoma (31), cervical cancer (32), and laryngeal carcinoma (33). This evidence concerns the gene ANG and renal cell carcinoma.